Ann A Jakubowski

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias
    Ying Yan
    The Saint Luke s Cancer Institute, 4321 Washington, Suite 4000 Kansas City, Missouri 64111, USA
    J Hematol Oncol 2:51. 2009
  2. pmc T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1335-42. 2011
  3. pmc T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Blood 110:4552-9. 2007
  4. pmc Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution
    Yeon Joo Lee
    Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 19:387-92. 2013
  5. doi request reprint Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant
    Jenna D Goldberg
    a Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma . 2017
  6. pmc T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 19:208-13. 2013
  7. pmc Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
    Miguel Angel Perales
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 120:4882-91. 2012
  8. pmc Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT)
    Mary Pao
    Memorial Sloan Kettering, New York, New York 10065, USA
    Biol Blood Marrow Transplant 14:1022-30. 2008
  9. pmc Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation
    Pere Barba
    Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Hematology Department, Hospital Universitario Vall d Hebron Universidad Autónoma de Barcelona, Barcelona, Spain
    Biol Blood Marrow Transplant . 2016
  10. pmc Adenovirus Viremia in Adult CD34(+) Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact
    Yeon Joo Lee
    Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, Cornell University, New York, New York
    Biol Blood Marrow Transplant 22:174-8. 2016

Collaborators

Detail Information

Publications30

  1. pmc Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias
    Ying Yan
    The Saint Luke s Cancer Institute, 4321 Washington, Suite 4000 Kansas City, Missouri 64111, USA
    J Hematol Oncol 2:51. 2009
    ..Patients whose leukemic blasts grew indolently or whose leukemia cells failed to induce growth had a significantly longer DFS and more favorable clinical course...
  2. pmc T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1335-42. 2011
    ..There was 1 late graft failure. This study demonstrates durable engraftment with a low overall incidence of GVHD. Its curative potential is reflected in the remarkably low relapse rate at 4 years...
  3. pmc T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10065, USA
    Blood 110:4552-9. 2007
    ..Life-threatening OIs occurred in 3 of 52 patients and was fatal in 1. This study demonstrates durable engraftment with a low incidence of GvHD despite the lack of ATG, as well as the curative potential of this regimen...
  4. pmc Adenovirus viremia and disease: comparison of T cell-depleted and conventional hematopoietic stem cell transplantation recipients from a single institution
    Yeon Joo Lee
    Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Biol Blood Marrow Transplant 19:387-92. 2013
    ..The benefit of preemptive therapy for an ADV viral load ≥10,000 copies/mL for preventing ADV disease in TCD HSCT recipients should be evaluated in prospective clinical trials...
  5. doi request reprint Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant
    Jenna D Goldberg
    a Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma . 2017
    ..In conclusion, T-cell recovery is an important predictor of outcome after TCD allo-HSCT...
  6. pmc T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 19:208-13. 2013
    ..15 (95% CI, 0.04-0.26), and that of extensive chronic GVHD at 2 and 5 years was 0.05 (95% CI, 0-11.6). We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD...
  7. pmc Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
    Miguel Angel Perales
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 120:4882-91. 2012
    ..Our results indicate that r-hIL-7 can enhance immune recovery after a T cell-depleted allo-HSCT without causing significant GVHD or other serious toxicity (www.clinicaltrials.gov; NCT00684008)...
  8. pmc Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT)
    Mary Pao
    Memorial Sloan Kettering, New York, New York 10065, USA
    Biol Blood Marrow Transplant 14:1022-30. 2008
    ..Prospective, multicenter trials assessing the best strategy to administer this vaccine and its impact on pneumococcal infections following transplantation are warranted...
  9. pmc Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation
    Pere Barba
    Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Hematology Department, Hospital Universitario Vall d Hebron Universidad Autónoma de Barcelona, Barcelona, Spain
    Biol Blood Marrow Transplant . 2016
    ....
  10. pmc Adenovirus Viremia in Adult CD34(+) Selected Hematopoietic Cell Transplant Recipients: Low Incidence and High Clinical Impact
    Yeon Joo Lee
    Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, Cornell University, New York, New York
    Biol Blood Marrow Transplant 22:174-8. 2016
    ..Further studies are needed to assess the impact of preemptive treatment with brincidofovir on improving outcomes of ADV infections in this patient population...
  11. pmc CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse
    Roni Tamari
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York Electronic address
    Biol Blood Marrow Transplant 21:2106-14. 2015
    ..These findings demonstrate that ex vivo T cell-depleted allo-HSCT by CD34 selection offers long-term OS and RFS with low incidences of acute and chronic GVHD and without an increased risk of relapse...
  12. pmc High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York Electronic address
    Biol Blood Marrow Transplant 21:1985-93. 2015
    ....
  13. pmc Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study
    Susan K Seo
    Department of Medicine, Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, USA Electronic address
    J Infect 69:341-51. 2014
    ..We analyzed the effect of peri-transplant prophylaxis on the epidemiology of bacteremia in a 12-year contemporary cohort of allogeneic HSCT recipients at our center...
  14. pmc A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies
    Craig S Sauter
    Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 55:2739-47. 2014
    ....
  15. pmc A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients
    Craig S Sauter
    Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Cornell Medical College, New York, New York Electronic address
    Biol Blood Marrow Transplant 20:354-60. 2014
    ..001). This nonmyeloablative regimen, with peritransplant rituximab, is safe and effective in patients with B-NHL...
  16. pmc Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation
    Yao Ting Huang
    Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
    Biol Blood Marrow Transplant 22:1480-6. 2016
    ..CMV viremia occurred in 70% of R + TCD-HCT. Delay in PET initiation was associated with persistent viremia. With PET, CMV R/D serostatus did not adversely impact survival in TCD-HCT on 1-year survival in the present cohort. ..
  17. pmc Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 53:1124-9. 2012
    ..These data demonstrate that allogeneic transplant is a viable option for the treatment of T-NHL and merits prospective evaluation...
  18. pmc Relationship of BK polyoma virus (BKV) in the urine with hemorrhagic cystitis and renal function in recipients of T Cell-depleted peripheral blood and cord blood stem cell transplantations
    Yeon Joo Lee
    Department of Medicine, Infectious Disease, Memorial Sloan Kettering Cancer Center, New York, New York
    Biol Blood Marrow Transplant 20:1204-10. 2014
    ..Cr and CrCl at 2, 3, and 6 months after HSCT were similar between patients with and without BK viruria. ..
  19. pmc Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1316-26. 2011
    ..482). These data provide strong support for the further investigation of double-unit CB grafts as an alternative hematopoietic stem cell source...
  20. pmc The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients
    Mini Kamboj
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Biol Blood Marrow Transplant 16:1576-81. 2010
    ..The use of alternate agents with activity against Gram-positive bacteria for fever and neutropenia early after HSCT should be evaluated further in prospective studies...
  21. doi request reprint Ex Vivo CD34+ Selected T-Cell Depleted (TCD) Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome is Associated with Low Incidence of Acute and Chronic Graft-Versus-Host Di
    Pere Barba
    Adult Bone Marrow Transplant Service, Division of Hematology Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Hematology Department, Hospital Universitario Vall d Herbon, Universidad Autonoma de Barcelona
    Biol Blood Marrow Transplant . 2016
    ..Our findings support the use of ex vivo CD34+ selected TCD allograft as a calcineurin inhibitor-free intervention for the prevention of GVHD in patients with acute leukemia and MDS...
  22. pmc Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation
    Brian C Shaffer
    Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York
    Biol Blood Marrow Transplant 22:705-9. 2016
    ..In summary, our data support the safety of haploidentical NK cell infusion after allogeneic HCT...
  23. pmc Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027
    Mini Kamboj
    Services of Infectious Diseases, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Department of Medicine, Weill Medical College of Cornell University, New York, New York Electronic address
    Biol Blood Marrow Transplant 20:1626-33. 2014
    ..Despite the high prevalence of NAP1/027, the disease is mild but relapses are common. No association was found between CDI and subsequent development of GI GVHD. ..
  24. doi request reprint Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease
    Anna Maria Delios
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Neurooncol 110:251-6. 2012
    ..Response to immune modulators suggests an immune-based etiology. The incidence of de novo autoimmune disease after HSCT for hematological diseases is rare and may be difficult to differentiate from GVHD...
  25. pmc Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation
    Ilya G Glezerman
    Department of Medicine, Renal Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Biol Blood Marrow Transplant 16:976-84. 2010
    ..0006) predisposed patients to the development of HTN using univariable logistic regression models. Thus, despite the absence of CNI, a proportion of these older patients in both groups developed CKD and HTN...
  26. ncbi request reprint Novel approaches in allogeneic stem cell transplantation
    Esperanza B Papadopoulos
    Department of Medicine, Adult Allogeneic Bone MarrowTransplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Oncol Rep 8:325-36. 2006
    ..These developments provide physicians with the ability to tailor transplants to specific patients and their diseases...
  27. ncbi request reprint Short- and long-term outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peritransplant period
    Sebastian Mayer
    a Department of Medicine, New York Presbyterian Hospital, Joan and Sanford I Weill Medical College, Cornell University, New York, USA
    Leuk Lymphoma 58:382-390. 2017
    ..Late deaths, due to causes not associated with the ICU such as relapse and graft-versus-host disease, increased. As thresholds for transplant are lowered, improvements in ICU outcomes for aHSCT recipients may be limited...
  28. pmc Histopathologic Features of Cutaneous Acute Graft-Versus-Host Disease in T-Cell-Depleted Peripheral Blood Stem Cell Transplant Recipients
    Alyssa Fischer
    Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY Department of Pathology, Dermatopathology, Memorial Sloan Kettering Cancer Center, New York, NY Department of Medicine, Division of Dermatology, University of Toronto, Toronto, Canada Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY and Department of Pediatrics, Weill Cornell Medical College, Cornell University, New York, NY
    Am J Dermatopathol 37:523-9. 2015
    ..Awareness of these features may help when evaluating a skin rash occurring after a TCD transplant. ..
  29. doi request reprint Retrospective outcome data for hematopoietic stem cell transplantation in patients with concurrent coronary artery disease
    Elizabeth E Stillwell
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Biol Blood Marrow Transplant 17:1182-6. 2011
    ..1% versus 9.9%, P = .686), or length of stay (25.5 days versus 28.4 days, P = .195). These findings suggest many patients with underlying coronary artery disease may be safely managed through hematopoietic stem cell transplantation...
  30. pmc Imaging therapeutic response in human bone marrow using rapid whole-body MRI
    Douglas Ballon
    Department of Radiology, Weill Medical College of Cornell University, New York, New York 10021, USA
    Magn Reson Med 52:1234-8. 2004
    ..Examples presented include the evaluation of therapeutic response in bone marrow during cytotoxic therapy for leukemia and metastatic prostate cancer and during cytokine administration for marrow mobilization prior to stem cell harvest...